Dako, an Agilent Technologies Company, Launches Two Ready-to-Use Antibodies for Cancer Diagnosis

        Print
| Source: Dako Denmark A/S

GLOSTRUP, Denmark, May 2, 2014 (GLOBE NEWSWIRE) -- Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions , today announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software.

Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by pathologists to stain CK 8/18 in tissue samples and thereby help classify tumors of unknown origin. Keratins are one of the most potent epithelial differentiation and tumor markers in cancer diagnostics.

Anti-TdT, also a rabbit monoclonal antibody, is used to help classify lymphoma and leukemia by staining terminal deoxynucleotidyl transferase (TdT) in tissue samples. In immunohistochemistry, antibodies to TdT can be used to demonstrate the presence of pre-T and pre-B cells and multipotent hematopoietic stem cells that possess the antigen.

Both Anti-CK 8/18 and Anti-TdT provide excellent specificity and sensitivity and have been reviewed and accepted by key pathology experts. Both antibodies provide optimal staining results enabled by the FLEX Ready-to-Use Dako solutions.

FLEX Ready-to-Use is a plug-and-play solution consisting of pre-diluted antibodies, a visualization system, and optimized validated protocols developed in collaboration with leading pathology experts. The protocols are developed to take into account pre-analytical variations and different ways of processing and handling tissue samples, ensuring optimal staining results for pathology labs.

"With the FLEX RTU solution, it takes less time for a lab to validate new antibodies for routine diagnostic use," said Hans Christian Pedersen, global product manager, Dako IHC reagents. "FLEX Ready-to-Use antibodies are helping labs get high-quality results from day one."

"We are pleased to add these two high-quality antibodies to our comprehensive offering to pathologists around the world," said Britt Meelby Jensen, vice president of Marketing and Pathology Sales in Agilent's Diagnostics and Genomics business. "One of our goals is to constantly establish new quality benchmarks within IHC reagents."

Both products are available from Dako now as 1.0 mL concentrates and 12 mL (60 tests) FLEX RTUs for Autostainer Link 48.

Editorial Contacts
Dako Products and Solutions for Pathology
Victoria Wadsworth-Hansen
victoria.wadsworth-hansen@agilent.com
+45 29336980

Media and Press
Maia Fredtoft Søchting
maia.sochting@agilent.com
+45 25461083

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Agilent acquired Dako in 2012, a well-known provider of reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Information about Agilent is available at www.agilent.com and information about Dako products is available at www.dako.com.

On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.

HUG#1782272